Absorption and biological effect of intraperitoneal insulin administration in patients with terminal renal failure treated by continuous ambulatory peritoneal dialysis (CAPD).
D000042:Absorption; D001682:Biological Availability; D002096:C-Peptide / Q000097:blood; D005947:Glucose / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D010529:Peritoneal Cavity / Q000378:metabolism; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013997:Time Factors
D002096:C-Peptide; D007328:Insulin; D005947:Glucose